ISCOM based vaccines for cancer immunotherapy.
Vaccine
; 22(8): 963-74, 2004 Feb 25.
Article
en En
| MEDLINE
| ID: mdl-15161073
ABSTRACT
Immunostimulating complex (ISCOM) vaccines are particulate antigen delivery vehicles composed of saponin, cholesterol, phospholipid and immunogen. Here we illustrate that ISCOM-based vaccines represent an attractive modality for the development of anti-cancer vaccines. Using murine models and a model cancer antigen, ISCOM vaccines were shown to induce potent CD8 T cell responses, to mediate protection in three different tumor models, to promote Th1-biased immunity, and to induce CD8 T cell responses in the absence of CD4+ T cell help. The former three activities were also found to be substantially improved when the vaccine antigen was associated with the ISCOM structure. Furthermore, the presence in vivo of pre-existing antibodies against the vaccine antigen did not inhibit CD8 T cell induction by the ISCOM vaccine. Although vaccination was effective against challenge with vaccine-antigen expressing tumors, no activity against neighboring vaccine-antigen negative tumor cells was observed, indicating that determinant spreading or bystander activity does not lead to significant anti-cancer activity.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
ISCOMs
/
Vacunas contra el Cáncer
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
Vaccine
Año:
2004
Tipo del documento:
Article
País de afiliación:
Australia